place

Holy Family Church (North Chicago, Illinois)

1915 establishments in IllinoisChurches completed in 1915Churches in the Roman Catholic Archdiocese of ChicagoChurches on the National Register of Historic Places in IllinoisGothic Revival architecture in Illinois
National Register of Historic Places in Lake County, IllinoisNorth Chicago, IllinoisNorthern Illinois Registered Historic Place stubs
Holy Family Church North Chicago
Holy Family Church North Chicago

Holy Family Church is a historic church at 1840 Lincoln Street in North Chicago, Illinois. The church was built in 1914-15 for North Chicago's Roman Catholic congregation, which was formed in 1901. Architect William F. Gubbins designed the Late Gothic Revival church. The church's design includes a front-facing gable with a large stained glass window, pointed arch windows, and a square bell tower with large louvered windows, all typical features of Gothic Revival architecture. The Catholic congregation used the church until 1991; it is now occupied by the Emmanuel Faith Bible Christian Center.The church was added to the National Register of Historic Places on August 21, 2003.

Excerpt from the Wikipedia article Holy Family Church (North Chicago, Illinois) (License: CC BY-SA 3.0, Authors, Images).

Holy Family Church (North Chicago, Illinois)
Argonne Drive,

Geographical coordinates (GPS) Address Nearby Places
placeShow on map

Wikipedia: Holy Family Church (North Chicago, Illinois)Continue reading on Wikipedia

Geographical coordinates (GPS)

Latitude Longitude
N 42.325 ° E -87.842777777778 °
placeShow on map

Address

Argonne Drive 904
60064
Illinois, United States
mapOpen on Google Maps

Holy Family Church North Chicago
Holy Family Church North Chicago
Share experience

Nearby Places

AbbVie
AbbVie

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. It developed Skyrizi ($7.8 billion in 2023 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5.7 billion in 2023 revenues), Imbruvica to treat cancer ($3.6 billion in 2023 revenues), Rinvoq to treat arthritis ($4 billion in 2023 revenues), Venclexta to treat leukemia and lymphoma ($2.3 billion in 2023 revenues), Vraylar to treat schizophrenia and bipolar disorder ($2.7 billion in 2023 revenues), and Mavyret to treat Hepatitis C ($1.4 billion in 2023 revenues).: 39–40  The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.: 34  In 2023, Humira began facing competition from a biosimilar developed by Amgen. The company is also developing a drug for Parkinson's disease that could be a blockbuster drug in 2027 and is awaiting approval from the Food and Drug Administration for epcoritamab, a blood-cancer therapy under development in partnership with Genmab. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.